Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Standard treatment for lung cancer should be changed, say scientists

24.09.2003


Patients with non-small cell lung cancer (NSCLC) are more likely to survive if they have chemotherapy after surgery than if they have surgery alone, said a scientist at ECCO 12 The European Cancer Conference in Copenhagen today (Tuesday 23 September). Dr. Bengt Bergman, of the Sahlgrenska University Hospital. Göteborg, Sweden, said that results from the International Adjuvant Lung Cancer Trial (IALT), which involved 1,867 patients in 33 countries, were sufficiently strong to recommend changing the standard treatment.



The randomised controlled trial showed an absolute 4.1% increase in survival after five years among those who had had adjuvant therapy with cisplatin, in combination with one of several other commonly-used cancer drugs. A 1995 meta-analysis of other trials showed a similar advantage for this therapy, but with only a borderline statistical significance since fewer patients with cisplatin treatment were included, said Dr. Bergman.

Recurrence of lung cancer was also reduced in the cisplatin arm of the trial. After 5 years 24% of those taking cisplatin had a local recurrence, whereas this occurred in 29% of the control arm. The study found no interaction between dose or treatment combination and survival benefit.


The trial was the first with sufficient numbers of patients to show a statistically significant survival benefit from adjuvant chemotherapy in NSCLC, said Dr. Bergman. "Although a 4.1% improvement may not seem very much on which to base recommending a change in treatment, it is in line with results from other common malignancies such as breast, ovarian, and colon cancer, where the survival gain from adjuvant chemotherapy lies in the range of 3.5 – 8%. In all these cases adjuvant treatment is now part of the routine treatment."

However, toxicity remains a problem, he said. "There are potentially serious side effects to this treatment, and we need better tools to identify the patients who are most likely to benefit from adjuvant chemotherapy. The IALT project includes an extended research programme which aims to identify predictive tumour markers. And a planned joint analysis of the largest recent trials of adjuvant cisplatin-based therapy including more than 4,000 patients will better enable us to detect factors allowing us to predict treatment effects."


###

Emma Mason | EurekAlert!
Further information:
http://www.fecs.be/

More articles from Health and Medicine:

nachricht Remdesivir prevents MERS coronavirus disease in monkeys
14.02.2020 | NIH/National Institute of Allergy and Infectious Diseases

nachricht Recent advances in addressing tuberculosis give hope for future
12.02.2020 | NIH/National Institute of Allergy and Infectious Diseases

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Skyrmions like it hot: Spin structures are controllable even at high temperatures

Investigation of the temperature dependence of the skyrmion Hall effect reveals further insights into possible new data storage devices

The joint research project of Johannes Gutenberg University Mainz (JGU) and the Massachusetts Institute of Technology (MIT) that had previously demonstrated...

Im Focus: Making the internet more energy efficient through systemic optimization

Researchers at Chalmers University of Technology, Sweden, recently completed a 5-year research project looking at how to make fibre optic communications systems more energy efficient. Among their proposals are smart, error-correcting data chip circuits, which they refined to be 10 times less energy consumptive. The project has yielded several scientific articles, in publications including Nature Communications.

Streaming films and music, scrolling through social media, and using cloud-based storage services are everyday activities now.

Im Focus: New synthesis methods enhance 3D chemical space for drug discovery

After helping develop a new approach for organic synthesis -- carbon-hydrogen functionalization -- scientists at Emory University are now showing how this approach may apply to drug discovery. Nature Catalysis published their most recent work -- a streamlined process for making a three-dimensional scaffold of keen interest to the pharmaceutical industry.

"Our tools open up whole new chemical space for potential drug targets," says Huw Davies, Emory professor of organic chemistry and senior author of the paper.

Im Focus: Quantum fluctuations sustain the record superconductor

Superconductivity approaching room temperature may be possible in hydrogen-rich compounds at much lower pressures than previously expected

Reaching room-temperature superconductivity is one of the biggest dreams in physics. Its discovery would bring a technological revolution by providing...

Im Focus: New coronavirus module in SORMAS

HZI-developed app for disease control is expanded to stop the spread of the pathogen

At the end of December 2019, the first cases of pneumonia caused by a novel coronavirus were reported from the Chinese city of Wuhan. Since then, infections...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

70th Lindau Nobel Laureate Meeting: Around 70 Laureates set to meet with young scientists from approx. 100 countries

12.02.2020 | Event News

11th Advanced Battery Power Conference, March 24-25, 2020 in Münster/Germany

16.01.2020 | Event News

Laser Colloquium Hydrogen LKH2: fast and reliable fuel cell manufacturing

15.01.2020 | Event News

 
Latest News

Electric solid propellant -- can it take the heat?

14.02.2020 | Physics and Astronomy

Pitt study uncovers new electronic state of matter

14.02.2020 | Physics and Astronomy

Researchers observe quantum interferences in real-time using a new extreme ultra-violet light spectroscopy technique

14.02.2020 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>